Udayavni Special

UK becomes first country to approve Pfizer-BioNtech COVID-19 vaccine


Team Udayavani, Dec 2, 2020, 1:10 PM IST

 

London: The UK on Wednesday became the first country to approve the Pfizer/BioNTech vaccine against COVID-19, paving the way for mass vaccinations against the deadly novel coronavirus.

The British regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), says the jab, which claims to offer up to 95 per cent protection against COVID-19 illness, is safe for roll out.

The joint vaccine, produced by American pharmaceutical giant Pfizer and German biotech firm BioNTech, had recently claimed trials suggested it works well in people of all ages, races and ethnicities.

The UK government had asked the MHRA to look into the data to clear it for use if it meets “robust” standards of quality, safety, and effectiveness.

The UK is expected to receive a total of 40 million doses by the end of 2021, enough to vaccinate up to a third of the population, with the majority of doses anticipated in the first half of next year.

“If approval is granted, the NHS (National Health Service) will be ready to deliver. The NHS has vast experience in delivering widespread vaccination programmes and an enormous amount of work has taken place to ensure we have the logistical expertise, transport and workforce to roll out a vaccine according to clinical priority, at the speed at which it can be manufactured,” UK Health Secretary Matt Hancock had said last month.

The UK government stressed that the COVID-19 vaccine will only be authorised for supply by the UK’s independent regulator if it meets strict standards of quality, safety, and effectiveness, and if they are satisfied the vaccine can be consistently manufactured.

The MHRA is the UK’s independent regulator, hailed as a globally recognised institution for requiring the highest standards for quality, safety and effectiveness.

The vaccine will be manufactured in BioNTech’s German sites, as well as Pfizer’s manufacturing site in Belgium.

The UK government said it remains confident that the cold supply chain needed to distribute the Pfizer/BioNTech vaccine will not cause any problems or delays. When the vaccine is stored in a fridge, it has an effective life of up to five days at temperatures of 2 to 8 degrees, which will allow it to be easily stored at distribution centres.

Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.

Top News

PM visits Netaji’s ancestral home in Kolkata

WHO chief Ghebreyesus thanks PM Modi for ‘continued support’ to global COVID-19 response

Chinese military personnel to get ‘bumper’ pay hike: media report

BSF detects underground tunnel along IB in J-K’s Kathua, second within 10 days

Illegal quarrying or mining will not be allowed in the state: CM

Farmer unions meet to reconsider govt proposal of putting farm laws on hold

Yelagur police makes first arrest under new anti-cattle law in K’taka


Related Articles More

WHO chief Ghebreyesus thanks PM Modi for ‘continued support’ to global COVID-19 response

Chinese military personnel to get ‘bumper’ pay hike: media report

New UK variant of coronavirus may be more deadly, says Boris Johnson

Too early to draw Covid-19 origin conclusions: WHO

Bilawal Bhutto pitches for no-confidence motion to oust Imran Khan-led Pak govt

MUST WATCH

Compol appeals people to share info regarding any untoward developments through Whatsapp

Mangaluru: Police arrest nine students for alleged ragging

Remembering Netaji Subhas Chandra Bose | Asha Raghuvamshi

Inter-state Ganja smuggling racket busted: 7 held, 44.630 kgs of Marijuana seized

explosion sound around shivamogga

Latest Additions

PM visits Netaji’s ancestral home in Kolkata

WHO chief Ghebreyesus thanks PM Modi for ‘continued support’ to global COVID-19 response

Will recommend strict action against Yatnal: Nalin Kumar Kateel

Being targeted through false propaganda, manufactured online campaign says Adani Group

Kaup: Timely intervention by policeman saves many lives

Thanks for visiting Udayavani

You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.